CTIS2023-503584-42-00进行中（未招募）1 期
An open-label, cross-over, multi-site, prospective, phase IIb study of effects on circadian rhythms and quality of life of modifieddual-release hydrocortisone Efmody™ versus immediate-release hydrocortisone in patients with Addison’s Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Male or female participants must be aged 18 years or older, 2. Ability to comprehend the Patient Information Leaflet and to provide signed and dated informed consent., 3. Participants with an established diagnosis of Addison’s disease currently treated with immediate-release hydrocortisone as replacement therapy ., 4. Participants on stable immediate-release hydrocortisone treatment for = 4 weeks prior to enrolment., 5. Participants on a stable dose of fludrocortisone for = 4 weeks prior to enrolment, 6. Evidence of effective contraception for WOCBP* (see Appendix 11) *Women of childbearing potential (WOCBP) are eligible to participate if they are not pregnant, not breastfeeding and agree to adhere to the contraceptive guidance during the screening and treatment periods. Effective contraception should be maintained until treatment discontinuation. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. The effective methods of contraception are described in Appendix 11, 7. In the Investigator’s opinion, able and willing to comply with all trial requirements.
排除标准
- •Participants aged < 18 years, Conditions that would place the individual at increased risk or preclude the individual’s full compliance with or completion of the study – such as intellectual disability or cognitive impairment, Patients who have difficulty understanding the required protocol and follow up instructions (e.g. language barriers), Participants with life expectancy of less than 6 months., Participants with a history of malabsorption and/or motility disorders due to risk of impaired cortisol exposure., Participants treated with agents that interfere with corticosteroid metabolism., Participants who have received intra-articular steroid injections within 2 months prior to the Screening Visit or for whom such injections are planned during the study., Participants who are prescribed inhaled or topical steroid preparations, Participants with ongoing use of drugs which affect sleep - such as sedatives or antidepressants., Patients who have participated in another research trial involving an investigational product in the past 12 weeks., Ongoing habitual alcohol intake in excess of 20 units per week., Clinical or biochemical evidence of hepatic disease: elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 times the upper limit of normal [ULN])., History of night-shift work in the previous two years, Participants who intend to travel and cross a time zone of greater than ±3 hours within 1 week of the scheduled actigraphy and DLMO measurements., Participants with a known hypersensitivity to any of the components of the Efmody™ capsules., Pregnancy, Breastfeeding Mothers, Clinical or biochemical evidence of renal disease: serum creatinine level of >221 µmol/L (2.5 mg/dL) or calculated creatinine clearance of <25 mL/min., Participants who have type 1 diabetes or type 2 diabetes receiving regular insulin., Participants who have elective surgical procedures scheduled during the study., Current diagnosis of moderate to severe depression, bipolar disorder, eating disorders, schizophrenia or other psychosis. A past history of psychiatric disorder is not an exclusion criterion, provided the patient is currently well (not on psychoactive treatment) in the investigator’s judgement. Participants with psychiatric conditions that in the opinion of the Investigator would preclude participation in the study: such as severe depression, schizophrenia, eating disorders., Participants with an acute medical or surgical illness., History of significant medical co-morbidities which disrupt sleep (for example, obstructive sleep apnoea, congestive cardiac failure or restless leg syndrome), History of cataracts or other ophthalmologic conditions which could affect retina light perception.
研究者
相似试验
已完成
4 期
A Prospective, Open-label, Non-comparative, Multi-centric Active PMS to evaluate efficacy and safety of STOMAFIT ORAL LIQUID containing Liquor Bismuth Ammonium Citrate 2.5ml, Belladonna Dry Extract 9mg, Thymol 0.15mg and Menthol 0.2 mg in Gastritis or Gastroesophageal Reflux Disease (GERD)CTRI/2020/03/023787SUNCARE FORMULATIONS PVT LTD200
招募中
4 期
A observational study to check the effectiveness and safety of ceritinib in patients with non small cell lung cancer who are ALK positive and who have progessed to crizotinibCTRI/2016/09/007291ovartis Healthcare Pvt Ltd50
已完成
4 期
A Study to Assess safety of Canagliflozin and Metformin Hydrochloride Combination Given as a Supplement to Diet and Exercise to Improve Blood Sugar Level in Indian Adult Participants with DiabetesCTRI/2020/07/026539Johnson and Johnson Private Limited276
招募中
4 期
TRIOX: A post marketing study on the effects and safety of Trioptal in patients with newly diagnosed epilepsyCTRI/2010/091/001239ovartis India LimitedSandoz House, 5th floorShivsagar EstateDr. Annie Besant RoadIndia500
招募中
4 期
A clinical study to evaluate the efficacy and safety of Levonorgestrel Intrauterine System (Emily) in Indian womenwith Dysfunctional Uterine BleedingCTRI/2012/07/002843HLL Lifecare Limited75